AIMS: To develop a population pharmacokinetic model for maraviroc, a noncompetitive CCR5 antagonist, after oral administration of tablets to healthy volunteers and asymptomatic HIV-infected subjects and to quantify the inherent variability and influence of covariates on the parameters of the model. METHODS: Rich pharmacokinetic data available from 15 studies in healthy volunteers (n = 365) and two studies in asymptomatic HIV-infected subjects (n = 48) were analysed using NONMEM. Maraviroc was administered as single or multiple oral tablet doses under fasted and fed conditions. Doses ranged from 100 to 1800 mg day(-1). RESULTS: A two-compartment model parameterized to separate out absorption and clearance components on bioavailability was used. Absorption was described by a lagged first-order process. A sigmoid E(max) model described the effect of dose on absorption. A visual predictive check and nonparametric bootstrap evaluation confirmed that the model was a good description of the data. Typical CL, V(c) and V(p) values for a 30-year-old non-Asian are 51.5 l h(-1), 132 l and 277 l, respectively. CONCLUSIONS: For the typical non-Asian subject, fasted bioavailability increased asymptotically with dose from 24% at 100 mg to 33% at 600 mg. A high-fat meal taken with maraviroc reduced exposure by 43% for a 100-mg dose to approximately 25% at doses of 600 mg. The typical Asian subject had a 26.5% higher AUC than the typical non-Asian subject irrespective of dose, a difference not considered to be clinically relevant. None of the other covariates tested had any clinically relevant effects on exposure.
AIMS: To develop a population pharmacokinetic model for maraviroc, a noncompetitive CCR5 antagonist, after oral administration of tablets to healthy volunteers and asymptomatic HIV-infected subjects and to quantify the inherent variability and influence of covariates on the parameters of the model. METHODS: Rich pharmacokinetic data available from 15 studies in healthy volunteers (n = 365) and two studies in asymptomatic HIV-infected subjects (n = 48) were analysed using NONMEM. Maraviroc was administered as single or multiple oral tablet doses under fasted and fed conditions. Doses ranged from 100 to 1800 mg day(-1). RESULTS: A two-compartment model parameterized to separate out absorption and clearance components on bioavailability was used. Absorption was described by a lagged first-order process. A sigmoid E(max) model described the effect of dose on absorption. A visual predictive check and nonparametric bootstrap evaluation confirmed that the model was a good description of the data. Typical CL, V(c) and V(p) values for a 30-year-old non-Asian are 51.5 l h(-1), 132 l and 277 l, respectively. CONCLUSIONS: For the typical non-Asian subject, fasted bioavailability increased asymptotically with dose from 24% at 100 mg to 33% at 600 mg. A high-fat meal taken with maraviroc reduced exposure by 43% for a 100-mg dose to approximately 25% at doses of 600 mg. The typical Asian subject had a 26.5% higher AUC than the typical non-Asian subject irrespective of dose, a difference not considered to be clinically relevant. None of the other covariates tested had any clinically relevant effects on exposure.
Authors: Maria C Rosario; Bill Poland; John Sullivan; Mike Westby; Elna van der Ryst Journal: J Acquir Immune Defic Syndr Date: 2006-06 Impact factor: 3.731
Authors: Gerd Fätkenheuer; Anton L Pozniak; Margaret A Johnson; Andreas Plettenberg; Schlomo Staszewski; Andy I M Hoepelman; Michael S Saag; Frank D Goebel; Jürgen K Rockstroh; Bruce J Dezube; Tim M Jenkins; Christine Medhurst; John F Sullivan; Caroline Ridgway; Samantha Abel; Ian T James; Mike Youle; Elna van der Ryst Journal: Nat Med Date: 2005-10-05 Impact factor: 53.440
Authors: Maria C Rosario; Philippe Jacqmin; Pat Dorr; Elna van der Ryst; Chris Hitchcock Journal: Clin Pharmacol Ther Date: 2005-09-28 Impact factor: 6.875
Authors: Samantha Abel; Deborah Russell; Lyndsey A Whitlock; Caroline E Ridgway; Angus N R Nedderman; Donald K Walker Journal: Br J Clin Pharmacol Date: 2008-04 Impact factor: 4.335
Authors: Don K Walker; Samantha Abel; Pierre Comby; Gary J Muirhead; Angus N R Nedderman; Dennis A Smith Journal: Drug Metab Dispos Date: 2005-01-13 Impact factor: 3.922
Authors: Samantha Abel; Deborah Russell; Lyndsey A Whitlock; Caroline E Ridgway; Angus N R Nedderman; Donald K Walker Journal: Br J Clin Pharmacol Date: 2008-04 Impact factor: 4.335
Authors: Samantha Abel; Elna van der Ryst; Maria C Rosario; Caroline E Ridgway; Christine G Medhurst; Richard J Taylor-Worth; Gary J Muirhead Journal: Br J Clin Pharmacol Date: 2008-04 Impact factor: 4.335
Authors: Nithya Srinivas; Mackenzie Cottrell; Kaitlyn Maffuid; Heather A Prince; Julie A E Nelson; Nicole White; Craig Sykes; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Daniel Gonzalez; Angela D M Kashuba Journal: Antimicrob Agents Chemother Date: 2020-01-27 Impact factor: 5.191